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Abstract 
The impact of misspecifying covariance matrices at the second and the third levels of the three-
level model on inferences regarding the overall treatment effect and (co)variances estimates is 
evaluated by means of a simulation study and an empirical illustration is given. The results 
indicate that ignoring an existing covariance has no effect on the treatment effect estimate. In 
addition, the between-case variance estimates are unbiased and well estimated either when 
covariance is modeled or ignored. If the research interest lies in the between-study variance 
estimate, including at least 30 studies is warranted to get unbiased and precise estimates. 
Modeling covariance does not result in less biased and more precise between-study variance 
estimates as the between-study covariance estimate is extremely biased. As a consequence, 
single-case researchers can use either the model ignoring or modeling covariance when the 
research interest lies in the overall treatment effect estimate and/or the between-case variance. 
In addition, when the research interest lies on the between-case covariance, the model including 
covariance results in unbiased between-case variance estimates. The three-level model appears 
to be less appropriate to estimate the between-study variance if less than 30 studies are included.  
Keywords: Multilevel modeling; multiple-baseline across cases designs; covariance 
misspecification; Monte Carlo simulation study 
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The Consequences of Misspecifying Covariance Structures in Multilevel Models for Single-
Case Data: A Monte Carlo Simulation Study 
Single-case experimental designs make important contributions to the field of 
educational research (National Research council, 2002; Odom, Brantlinger, Gersten, Horner, 
Thompson, & Harris, 2005). For instance, this kind of design can be applied to evaluate specific 
interventions to reduce challenging behavior in persons with intellectual disabilities or to search 
for strategies for persons with learning disabilities. Although single-case designs (SCDs) are 
increasingly popular (Kazdin, 2011), the quantitative analysis of study results obtained with this 
kind of design is still developing (Kratochwill et al., 2010). The results of a SCD study 
investigating the effect of an intervention are especially informative for the specific case under 
investigation, but it is hard to generalize conclusions to other cases. To investigate 
generalizability of the SCD results across cases, one can collect information for several cases, 
as is done in the multiple-baseline design (MBD) across cases. In this type of design, an AB 
phase design is implemented simultaneously to different cases, while the start point of the 
treatment is staggered (as in Figure 1) across the cases (Ferron & Scott 2005; Onghena, 2005; 
Onghena & Edgington, 2005).  
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Figure 1. Graphical display multiple-baseline design across cases using hypothetical data. The 
start of the treatment is after session 3, session 7, and session 10 for Case 1, Case 2, and Case 
3 respectively.  
The MBD is growing in popularity because external events, which are random 
unexpected events influencing the outcome scores, can be disentangled from treatment effects. 
These external events might affect the outcome scores of several cases at the same time, while 
treatment effects are expected to occur immediately after the treatment starting point which is 
case-specific (Barlow, Nock & Hersen, 2009; Kinugasa, Cerin, & Hooper, 2004; Koehler & 
Levin, 2000). 
To combine multiple cases’ data, multilevel models can be used. Multilevel models are 
extensions of linear models and make it possible to synthesize treatment effects across cases 
and studies. When combining SCD data from several MBD studies, a three-level hierarchical 
structure can be modeled: measurement occasions (i.e., first level units) are nested within cases 
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(i.e., second level units), which in turn are nested within studies (i.e., third level units). For 
example, consider K studies (k = 0, 1,…, K), with Jk cases in study k (j = 0, 1,…Jk), and Ijk 
measurements for case j from study k (i = 0, 1,…Ijk). At level one, the continuous response 
variable can be modeled, for instance, using the following regression equation: 
𝑌𝑖𝑗𝑘 = 𝛽0𝑗𝑘 + 𝛽1𝑗𝑘𝐷𝑖𝑗𝑘 + 𝑒𝑖𝑗𝑘 with 𝑒𝑖𝑗𝑘~𝑁(0, 𝜎𝑒
2) (1) 
and the errors, the eijk’s, are assumed to be independently, identically, and normally distributed. 
The score on the continuous dependent variable on measurement occasion i for case j from 
study k (Yijk ) depends on a binary coded treatment indicator (𝐷𝑖𝑗𝑘), indicating whether 
measurement occasion i from case j within study k belongs to the baseline phase (𝐷𝑖𝑗𝑘 = 0) or 
the treatment phase (𝐷𝑖𝑗𝑘 = 1).  
Equation 1, regressing 𝑌𝑖𝑗𝑘 on 𝐷𝑖𝑗𝑘 contains two coefficients: 𝛽0𝑗𝑘 is the intercept and 
indicates the expected baseline level, and 𝛽1𝑗𝑘 refers to the treatment effect (i.e., the difference 
between the estimated outcome score under the treatment phase and the estimated outcome 
score under the baseline phase). SCD researchers are mainly interested in 𝛽1𝑗𝑘 because this 
coefficient provides information about the change associated with the introduction of the 
treatment. 
At the second level, the variation across cases can be modeled as follows: 
{
𝛽0𝑗𝑘 = 𝜃00𝑘 + 𝑢0𝑗𝑘
𝛽1𝑗𝑘 = 𝜃10𝑘 + 𝑢1𝑗𝑘
 with [
𝑢0𝑗𝑘
𝑢1𝑗𝑘
] ~𝑁 ([
0
0
] , [
𝜎𝑢0
2 𝜎𝑢0𝑢1
𝜎𝑢1𝑢0 𝜎𝑢1
2 ])  
(2) 
These equations indicate that the 𝛽 coefficients from Equation 1 randomly vary across cases, 
around study-specific means, the 𝜃 coefficients. The coefficients along the diagonal of the 
covariance matrix, 𝜎𝑢0
2 , 𝜎𝑢1
2 , indicate the between-case variance in the intercept, and the 
treatment effect, respectively. The off-diagonal coefficient represents the covariance. 𝜎𝑢0𝑢1 
indicates the covariance between the intercept and the treatment effect. It is for instance 
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reasonable to expect that participants with a higher baseline level will benefit less from the 
treatment and vice versa. 
At the third level, potential variability in the study-specific regression coefficients from 
the second level equations, the 𝜃 coefficients, is modeled. In the fullest model, the 𝜃 coefficients 
each equal an overall estimate across studies, indicated by the 𝛾 coefficients, and a random 
deviation from this average: 
{
𝜃00𝑘 = 𝛾000 + 𝑣00𝑘
𝜃10𝑘 = 𝛾100 + 𝑣10𝑘
  with [
𝑣00𝑘
𝑣10𝑘
] ~𝑁 ([
0
0
] , [
𝜎𝑣0
2 𝜎𝑣0𝑣1
𝜎𝑣1𝑣0 𝜎𝑣1
2 ])  
(3) 
Multilevel modeling entails the advantage that an overall treatment effect can be 
estimated, as well as variation between studies and cases in the treatment effect, or study- and 
case-specific treatment effects. Another major advantage of this multilevel approach is its 
flexibility. For instance, the model can be extended by including (additional) predictors at each 
level (e.g., time predictor at the first level, gender as case-specific predictor and average age as 
a study-specific predictor). Moreover, a specific structure for the variances and covariances at 
either level can be specified. 
Previous research indicates that multilevel modeling works appropriately to combine 
unstandardized (Owens & Ferron, 2012; Moeyaert, ugille, Ferron, Beretvas, & Van den 
Noortgate, 2013a ) and standardized (Moeyaert, Ugille, Ferron, Beretvas, & Van den Noortgate, 
2013b) SCD data across cases and studies. Estimation of the three-level model for SCD data 
was investigated, by evaluating the estimates of the overall treatment effect, 𝛾100, and of the 
between-case and between-study variance of the overall treatment effect. However, in previous 
studies, the between-case residuals were each assumed to be independently, identically, and 
normally distributed with mean zero and homogeneous variance, and thus a diagonal covariance 
structure was assumed at level-2. This might be an over-simplification of the between-case 
covariance structure. A non-zero covariance between residuals at level 2 seems reasonable, for 
instance, when due to a ceiling effect the treatment effect is expected to be smaller for cases 
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with an already high baseline level. In addition, these simulation studies made the same 
assumptions about the between-study residuals but again an unstructured covariance matrix, 
which allows the level-3 residuals to covary, may be more reasonable than a diagonal 
covariance structure. To date, no research has focused on the consequences of ignoring truly 
non-zero covariances in the context of multilevel modeling of SCD data. In most multilevel 
modeling software, the default option is to estimate an unconstrained covariance matrix for the 
random effects. However, given that there are two coefficients included in the level-1 regression 
equation, a total of 7 random effects covariance parameters have to be estimated, which 
complicates estimation especially in scenarios with small sample sizes and possible covariance 
values that are close to zero. Therefore there is a need to investigate if estimation of the 
multilevel model is robust to covariance matrix misspecification. If estimation is reasonably 
robust, then modeling of a simplified covariance matrix can be recommended for future studies 
using the three-level model in the context of SCD data.  
While previous research in the context of  multilevel modeling of SCD data mainly 
focused on the fixed effect estimates, there is some methodological research that has focused 
on specification of the residuals’ covariance matrix in contexts other than SCDs. For example, 
Singer and Willett (2003) argue that ignoring a covariance in a multilevel model in general may 
bias the estimation of the standard errors of the overall regression coefficients. This will in turn 
lead to distorted Type I error rates when testing the statistical significance regression 
coefficients and will affect estimation of the confidence intervals for the effects of interest. 
Kwok, West and Green (2007) investigated by means of a simulation study the misspecification 
of the within-case covariance structure in multiwave longitudinal multilevel models and found 
that the misspecification has a substantial impact on the variance estimates. Work by Berkhof 
and Kampen (2004) examine the effect of omitting a random coefficient in the multilevel 
models in general on the estimated variance components and the estimated variance of the 
treatment effects. They found that the consequences depend on the between-unit variance 
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proportions. Another study, by Van den Noortgate and Onghena (2005), investigated the effects 
of ignoring a level from a four level model (in the area of school effectiveness research) on the 
parameter estimates and standard errors. They found that the variance estimate of the ignored 
level is divided between the other levels and estimates of the standard errors of the fixed effects 
and the random components may change. 
Specifically for SCD data, the effects of level-1 residuals’ covariance misspecification 
have been studied before for a two-level model (Ferron, Bell, Hess, Rendina-Gobioff, 2009). In 
SCDs, it is reasonable that an external variable that influences an observation at a certain 
moment, also affects succeeding observations. This means that errors from succeeding 
occasions tend to be more alike than errors of occasions further in time (Kromrey & Foster-
Johnson, 1996). Ferron et al. (2009) found that not modeling autocorrelation in a two-level 
analysis of SCD data results in too small coverage proportions of the 95% confidence intervals 
and positively biased variance estimates. This same pattern of results also apply when level-1 
residuals’ autocorrelation is not modeled for the three-level model (Petit-Bois, Baek, & Ferron, 
2012). Level-2 and level-3 covariance misspecification issues in the SCD three-level modeling 
framework have not yet been investigated. The main focus of this paper is to examine the 
consequences of level-2 and level-3 covariance matrix misspecification which should provide 
a more complete understanding of misspecification issues in contexts of three-level modeling 
of SCD data. 
Simulation Study 
We conducted two simulation studies to evaluate estimation of the three-level model 
when freely estimating covariances between pairs of residuals at levels two and three of the 
three-level model. It might be possible to mathematically derive large-sample approximations 
of the estimated standard errors of the treatment effects. However, in the context of multilevel 
modeling of SCD data, researchers deal with very small sample sizes which violate asymptotic 
assumptions upon which the algebraic derivations would be based. Thus, we exclusively rely 
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on simulation studies to empirically examine estimation of model parameters and standard 
errors under the realistic sample size values that are typically encountered in applied SCD 
research in educational and social sciences. 
We simulated raw MBD across cases data using the three-level model, which is obtained 
by combining Equations 1 through 3:  
𝑌𝑖𝑗𝑘 = 𝑦000 + 𝑣00𝑘 + 𝑢0𝑗𝑘 + (𝛾100 + 𝑣20𝑘 + 𝑢2𝑗𝑘)𝐷𝑖𝑗𝑘 + 𝑒𝑖𝑗𝑘    (4) 
To estimate the three-level model parameters, the restricted maximum likelihood procedure in 
SAS 9.3 PROC MIXED was used (Littell, Milliken, Stroup, & Wolfinger, 2006). The Kenward-
Roger method was used to estimate the degrees of freedom because this method is accurate and 
appropriate for unbalanced designs and has the additional advantage that it corrects for small 
sample sizes in the variance estimation (Kenward & Roger, 1997).  
The criteria used to evaluate the overall treatment effect estimate across cases and across 
studies using the three-level analysis included the (relative) bias, the mean squared error (MSE), 
the relative standard error bias, and the coverage proportion of the 95% confidence intervals of 
the overall treatment effect  (i.e., 𝛾100). In contrast to previous simulation studies, we also 
evaluate the performance of the three-level modeling technique to estimate the variance 
components estimates (i.e., the between-case and the between-study variance of the treatment 
effect) and whether ignoring the covariance in the dataset has effects on the between-case 
variance and the between-study variance of the treatment effect in terms of the accuracy of the 
estimate (i.e., relative bias) and the precision of the estimate (i.e., MSE). 
The purpose of this study is to evaluate the performance of two multilevel models to 
estimate the overall treatment effect across cases and across studies and the between-case 
variance and the between-study variance of the treatment effect; one in which no covariance is 
estimated (i.e., Analysis Model 1) and one in which covariance is estimated (i.e., Analysis 
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Model 2). In order to evaluate these models in a systematic way, we conducted two simulation 
studies. 
In Simulation Study 1, we generated data without covariance between the baseline level 
and the treatment effect at both level 2 and level 3 and estimated the overall treatment effect 
and the variance components using Analysis Model 1 and Analysis Model 2. In Simulation 
Study 2, we generated covariance between the baseline level and the treatment effect on both 
level 2 and level 3 (taking on small and large values and crossing these values) and used again 
Analysis Model 1 and Analysis Model 2 to estimate the model parameters of interest. We are 
especially interested whether Analysis Model 2 results in more accurate and precise variance 
components estimates and less biased estimates of the standard error of the overall treatment 
effect. 
 For the first Monte Carlo simulation study, we varied six design conditions, namely the 
treatment effect (i.e., 𝛾100), the number of units at the three levels (i.e., the number of 
measurements at the first level, I, the number of cases at the second level, J, and the number of 
studies at the third level, K), and the between-case, and between-study variability (i.e., 𝜎𝑢1
2  
and 𝜎𝑢1
2  respectively). For Simulation Study 2, two additional design conditions were varied, 
namely the covariance between the baseline level and the treatment effect on both level 2 (i.e., 
𝜎𝑢0𝑢1) and level 3 (i.e., 𝜎𝑣0𝑣1). The conditions were fully crossed and 1,000 datasets were 
generated for each condition. 
In order to identify values for the design conditions that are authentic for SCD data 
encountered in the area of educational research, we re-analyzed published meta-analyses of 
SCD studies (Denis, Van den Noortgate, & Maes, 2011; Heyvaert, Maes, Van den Noortgate, 
Kuppens, & Onghena, 2011; Kokina & Kern, 2010; Shogren, Fagella-Luby, Bae, & Wehmeyer, 
2004; Wang, Cui, & Parrila, 2011). Based on the re-analysis, a median overall treatment effect 
of 2 was observed. In addition, we were also interested whether a zero treatment effect can be 
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recovered using the three-level model. Therefore, 𝛾100, was given a value of 0 or 2. As a 
consequence, data were generated such that the treatment causes an increase in outcome scores 
(e.g., the score on a math test). The regression coefficient indicating the baseline level (i.e., 
𝛾000) was not varied (and set to 0), because the focus of the current study is on the overall 
treatment effect estimate.  
The number of units at the three levels was varied. The highest level represents the study 
level. Each of these studies includes a limited number of cases (i.e., which represents the second 
level units) and in turn, in each case a number of measurement occasions is clustered (i.e., which 
is the lowest level). The number of simulated studies was set to 10 or 30 (K = 10 or 30) based 
on a review of social science single-case meta-analysis by Farmer, Owens, Ferron, and Allsopp 
(2010). They showed that 60% of the meta-analysis included less than 30 studies. We choose 
to test whether the multilevel model already works appropriate including lower limits for the 
number of studies. The number of cases simulated per study took on a value of 3 or 7 (J = 3 or 
7). These values are chosen based on the re-analysis of meta-analysis of single-cases (Denis et 
al., 2011; Heyvaert et al., 2011; Kokina & Kern, 2010; Shogren et al., 2004; Wang et al., 2011), 
on guidelines that MBDs have at least 3 baselines (Barlow, Nock & Hersen, 2009), on a review 
of MBD studies (Ferron, Farmer & Owens, 2010) illustrating that studies have between 3 to 10 
cases, on a survey of Shadish and Sullivan (2011) stating that the number of cases per study fell 
between 1 and 13 with a median of 3, and a review of Farmer et al. (2010) demonstrating that 
93% of studies included 7 or less than 7 cases. The generated number of measurement within a 
case varied and consisted of 20 or 40 measurement occasions (I = 20 or 40). Ferron et al. (2010) 
found a median of 24 measurements and Shadish and Sullivan (2011) found a similar value 
(i.e., 20) and documented that 90.6% of the cases had fewer than 49 data points. As we choose 
an MBD across cases’ designs, we staggered the introduction of the intervention across cases 
within studies. The staggering is a function of the total number of measurements and cases (see 
Table 1) within an MBD study. 
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Table 1 
Staggering of the Intervention’s Start Point as a Function of the Number of Cases (J) and 
Measurement Occasions (I) 
J j Start of treatment 
  I = 20 I = 40 
3 1 7 11 
 2 10 18 
 3 12 24 
7 1 7 11 
 2 9 15 
 3 9 15 
 4 11 21 
 5 13 27 
 6 13 27 
 7 15 31 
Note. The data in the simulation study were generated using an MBD across cases design and therefore the 
introduction of the intervention is staggered across cases within an MBD study. J indicates the number of cases (j 
= 1 to J) and I indicates the number of measurement occasions in one case. The cells of the last two columns 
represent the time at which the intervention is started. 
The within-case variance was generated with a variance of one and assumed to be 
homogeneous across phases. Level-2 and level-3 errors were generated from a normal 
distribution using the RANNOR random number generator in SAS. The between-case 
covariance matrix (i.e., Σ𝑢) was manipulated representing conditions with relatively small and 
relatively large amounts of between-case variance. In Simulation Study 1, the covariance was 
set to zero (at both the case and study level) and therefore in Simulation Study 1,  Σ𝑢 is a 
diagonal matric,  Σ𝑢 = 𝑑𝑖𝑎𝑔( 𝜎𝑢0
2 , 𝜎𝑢1
2 ). Our re-analyses of meta-analyses (Denis et al., 2011; 
Kokina & Kern, 2010; Shogren et al., 2004) indicated that the variances are twice or eight times 
larger than the within-case variance and therefore we chose values of 2 or 8:  Σ𝑢 = 
𝑑𝑖𝑎𝑔( 𝜎𝑢0
2 , 𝜎𝑢1
2 ) = diag (2 , 2) or  Σ𝑢 = 𝑑𝑖𝑎𝑔( 𝜎𝑢0
2 , 𝜎𝑢1
2 ) = diag (8 , 8). Again based on re-analyses 
of meta-analyses (Alen et al., 2009; Denis et al., 2011; Kokina & Kern, 2010; Shogren et al., 
2004; Wang et al., 2011), we have chosen the same sets of values for the two diagonal elements 
of the between-study variance. In Simulation Study 2, covariance between the intercept and the 
treatment effect were generated. Based on Alen et al. (2009); Denis et al. (2011); Kokina & 
Kern (2010); Shogren et al. (2004); Wang et al. (2011), negative covariances at level 2 and level 
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3 were generated, indicating that a rather large baseline level results in a rather small treatment 
effect estimate. In order to define the values for the covariance, we calculated the correlation 
between the baseline level and the treatment effect using the dataset obtained by the re-analyses 
of meta-analyses (Denis et al., 2011; Kokina & Kern, 2010; Shogren et al., 2004). We found 
that the correlation between the baseline level and the treatment effect on both level 2 and level 
3 ranged from -0.30 to -0.70 and therefore we choose to include this lower and upper limit. 
Using the correlation and the standard deviation of the baseline level and treatment (i.e., root of 
the variance), we can calculate the covariance between the baseline level and the treatment 
effect. For instance, for the covariance at the third level, we can calculate the between-study 
covariance by transforming Equation 5: 
𝑟𝑣0𝑣1 =  
𝜎𝑣0𝑣1
𝜎𝑣0  𝜎𝑣0  
 (5) 
For instance, if the correlation equals -.30 and the variances are set on 2 or 8 , then the 
covariance equals -0.60 or -2.40 respectively. On the other hand , if the correlation equals -.70 
and the variances are set on 2 or 8 , then the covariance equals -1.40 or -5.60 respectively. As a 
matter of clarity, the conditions for Simulation Study 1 and Simulation Study 2 are presented 
in Table 2. 
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Table 2 
Overview Design Conditions for Simulation Study 1 (i.e., no Covariance is Generated) and Simulation Study 2 (i.e., Covariance is Generated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. The values for the covariance at the second level (𝜎𝑢0𝑢1) and third level (𝜎𝑣0𝑣1) can take on two values representing a small correlation (r = -.30) and a large correlation (r = 
-.70) between baseline level and treatment level. The conditions were fully crossed and 1,000 datasets were generated for each condition.  
 Design Condition Notation  Design Condition Values 
    Simulation Study 1  Simulation Study 2 
1 Treatment effect 𝛾100  𝛾100 = 0 or 2 𝛾100 = 0 or 2 
2 Level-1 sample size (i.e., number of measurements) I  I = 20 or 40 I = 20 or 40 
3 Level-2 sample size (i.e., number of cases) J  J = 4 or 7 J = 4 or 7 
4 Level-3 sample size ( i.e., number of studies) K  K = 10 or 30 K = 10 or 30 
5 Between-case variance 
- Intercept 
- Treatment effect 
 
𝜎𝑢0
2   
𝜎𝑢1
2  
  
𝜎𝑢0
2 /𝜎𝑢1
2  = 2 or 8 
 
 
𝜎𝑢0
2 /𝜎𝑢1
2  = 2 or 8 
 
6 Between-study variance 
- Intercept 
- Treatment 
 
𝜎𝑣0
2   
 𝜎𝑣1
2  
 
𝜎𝑣0
2  / 𝜎𝑣1
2  = 2 or 8 
 
𝜎𝑣0
2  / 𝜎𝑣1
2  = 2 or 8 
 
7 Between-case covariance 𝜎𝑢0𝑢1   / If 𝜎𝑢0
2  / 𝜎𝑢1
2  = 2 then  𝜎𝑢0𝑢1  = -0.60 or -1.40 
If 𝜎𝑢0
2  / 𝜎𝑢1
2  = 8 then  𝜎𝑢0𝑢1  = -2.40 or -5.60 
8 Between-study covariance 𝜎𝑣0𝑣1   / If 𝜎𝑣0
2  / 𝜎𝑣1
2  = 2 then 𝜎𝑣0𝑣1 = -0.60 or -1.40 
If 𝜎𝑣0
2  / 𝜎𝑣1
2   = 8 then 𝜎𝑣0𝑣1  = -2.40 or -5.60 
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As a consequence, we examined a total of 26 = 64 conditions in Simulation Study 1 and 
28 = 256 conditions in Simulation Study 2. For each condition we simulated 1,000 datasets 
resulting in 64,000 and 256,000 datasets to analyze for Simulation Study 1 and  
Simulation Study 2 respectively. In Simulation Study 1, no covariance was generated in contrast 
to Simulation Study 2. In both simulation studies, the generated datasets were analyzed twice 
(i.e., Analysis Model 1 vs Analysis Model 2) using a three-level multilevel model with restricted 
maximum likelihood estimation via the MIXED procedure in SAS. In Analysis Model 1, the 
covariances at level 2 and level 3 between the baseline level and the treatment effect were 
constrained to zero, whereas in Analysis Model 2, the covariance components on both levels 
were freely estimated.  
We expect no differences between Model 1 and Model 2 in Simulation Study 1 (in which 
no covariance is generated). In Simulation Study 2, we expect biased standard error estimates 
of the treatment effect and less accurate and precise variance components when Analysis Model 
1 is used (i.e., covariance is generated but ignored in the analysis).  
Results 
First the results of Simulation Study 1 are presented in which no covariance between 
baseline level and treatment effect was generated followed by a second simulation study in 
which covariance was simulated. We used two-way ANOVAs (PROC GLM in SAS) as 
preliminary analyses to explore whether the bias, the MSE, the relative standard error bias and 
the coverage proportion of the 95% confidence interval of the overall treatment effect estimate 
depend on the analysis model (i.e. Analysis Model 1 vs Analysis Model 2) or certain design 
conditions. As indicted earlier (and displayed in Table 2), 6 design conditions (i.e., 𝛾200, K, I, 
J, 𝜎𝑢2
2 , 𝜎𝑣2
2 ) are evaluated in Simulation Study 1, whereas 8 design conditions are explored in 
Simulation Study 2 (i.e., 𝛾200, K, I, J, 𝜎𝑢2
2 , 𝜎𝑣2
2  , 𝜎𝑢0𝑢1, 𝜎𝑣0𝑣1). We did not only look at statistically 
significant main effects and interaction effects (p < .001), but we also calculated the eta squares 
as effect sizes to evaluate whether the estimated main effects and/or interaction effects have a 
Running head: MISSPECIFICATION OF COVARIANCE 16 
 
rather small (≤ .02), medium (.03-.25) or large (≥.26) effect (Cohen, 1988). In addition, we are 
interested in how accurate (evaluated by the relative bias) and precise (evaluated by the MSE) 
the variance components are estimated using the two different analysis models. The relative 
bias of the overall treatment effect estimate cannot be calculated when the population value is 
set to 0 and therefore we evaluate the absolute bias for the fixed effect estimates (i.e., difference 
between the estimated value and the true population effect). For the (co)variance estimate, it is 
possible to calculate the relative bias (i.e., absolute bias divided by the population value) as the 
population values are nonzero. Whenever it is possible it is preferred to evaluate the relative 
bias rather than the absolute bias as this takes into account the magnitude of the population 
effect. For the relative bias estimates and the relative standard error bias estimates, we 
considered .05 and .10 respectively as substantial (Hoogland & Boomsma, 1998).  
Simulation Study 1 
Bias and MSE of the overall treatment effect estimate. We first look at the absolute 
bias, which is generally defined as the mean difference between the estimated values and the 
population value. From the ANOVA, we conclude that the analysis model has no statistically 
significant and large effect on the bias [F(1, 128032) = 0.13, p = .720, ŋ̂𝟐 < .0001] and the 
MSE [F(1, 128032) = 0.690, p = .41, ŋ̂𝟐 < .0001] of the overall treatment effect estimate. As 
indicated in Table 3, only the amount of between-case variance has a statistically significant, 
but small effect on the relative bias [F(1, 128032) = 13.01, p < .001, ŋ̂𝟐 = .0001). The absolute 
bias ranges from 5.660×10-4 to 0.0736 and the largest bias is observed in the conditions 
characterized by a small amount of studies (K = 10) and a large amount of between-study 
variance (i.e., 𝜎𝑢1
2  = 8) as illustrated in Figure 2. 
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Figure 2. Graphical display of the influence of the between-case variance and the numher of 
studies on the bias of the overall treatment effect estimates in simulation study 1 (i.e., no 
covariance is generated). K indicates the number of studies. The graphical display is for a 
subset for conditions as similar patterns where found for the other combination of conditions. 
Analysis Model 1 (i.e., no covariance is estimated) is used, the overall baseline level is set to 
zero, the number of measurements and cases is set to 20 and 3 respectively, and the between-
study variance equals 2. 
In addition, we looked at the MSE, an important criterion indicating how precise the 
treatment effect is estimated. A small bias in treatment effect estimate does not necessarily 
imply a small MSE. It can be the case that the individual estimates vary a lot around the mean 
estimate. An interesting finding is that the number of cases [F(1, 128032) = 272.15, p < .001, 
ŋ̂𝟐 = .0018], the number of studies [F(1, 128032) = 9987.14, p < .001, ŋ̂𝟐 = .0660] and the 
amount of variance at level 2 [F(1, 128032) = 541.48, p < .0001, ŋ̂𝟐 = .0036] and level 3 [F(1, 
128032) = 9687.85, p < .0001, ŋ̂𝟐 = 0.0641] of the multilevel model have a statistically 
significant effect on the MSE of the estimated treatment effect. However, only the between-
study variance and the number of studies appear to have a medium effect as indicated by the ŋ̂𝟐 
(Cohen, 1988). All the other design conditions and interactions have a small effect as indicated 
in Table 3. From Figure 3 we can deduce that the larger the number of level-3 units and the 
smaller the between-study variance, the smaller the MSE. The MSE ranges from 0.073 to 1.120 
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and the largest MSE is identified when 10 studies, 3 cases, 40 measurement occasions, a large 
amount of between-case variance (i.e., 𝜎𝑢1
2  = 8) and a large amount of between-study variance 
(i.e., 𝜎𝑢1
2  = 8) in combination with a zero treatment effect is included, independent of the 
analysis model. 
 
Figure 3. Graphical display of the influence of the between-case variance and the numher of 
studies on the mean squared error of the overall treatment effect estimates in Simulation Study 
1 (i.e., no covariance is generated). K indicates the number of studies. The graphical display is 
for a subset for conditions as similar patterns where found for the other combination of 
conditions. Analysis Model 1 (i.e., no covariance is estimated) is used, the overall baseline 
level is set to zero, the number of measurements and cases is set to 20 and 3 respectively, and 
the between- study variance equals 2. 
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Table 3 
Results Simulation Study 1 (i.e., no Covariance is Generated) using Analysis Model 1 (no Covariance is Estimated). Evaluation of the Main Effects and Interaction Effects of 
Simulation Conditions on the Relative Bias, Mean Squared Error, Standard Error and Coverage Proportion of the 95% Confidence Interval of the Treatment Effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. *p < .001. ŋ̂2 reflects the magnitude of the main effects and/or interaction effects on the relative bias, mean squared error, relative standard error bias and coverage 
proportion of the 95% confidence interval. ŋ̂2 can take on values between 0 and 1 ( small: ŋ̂2 ≤ .02, medium: ŋ̂2 = .03-.25, and large: ŋ̂2 ≥.26, Cohen, 1988). 𝜃100 = immediate 
treatment effect, I, J, and K = number of measurements, cases, and studies respectively. Interactions between two independent variables are indicated with a * in between the two 
independent variables (e.g., 𝜃100*I indicates an interaction between the immediate treatment effect and the number of measurements). 
 Relative Bias Mean Squared Error Relative Standard Error Bias Coverage Proportion 95% 
Confidence Interval 
Independent 
Variable 
df F p ŋ̂2  F p ŋ̂2  F p ŋ̂2  F p ŋ̂2 
𝜃100 1 0.02 .889 <.0001  1.22 .270 <.0001  4.21 .043 .0271  2.86 0.094 .0210 
I 1 2.31 .128 <.0001  0.25 .616 <.0001  0.01 .928 .0001  0.40 0.527 .0030 
J 1 0.27 .604 <.0001  272.16* <.0001 .0018  1.50 .223 .0097  0.77 0.383 .0056 
K 1 2.79 .095 <.0001  9987.46* <.0001 .0660  11.90* .001 .0765  8.53 0.004 .0626 
𝜎𝑢1
2  1 13.01* <.0001 .0001  541.50* <.0001 .0036  0.77 .381 .0050  0.07 0.795 .0005 
𝜎𝑣2
2  1 0.38 .539 <.0001  9688.15* <.0001 .0641  1.86 .175 .0120  0.79 0.375 .0058 
𝜃100*I 2 0.13 .879 <.0001  0.69 .502 <.0001  0.01 .904 .0001  0.01 0.916 .0001 
𝜃100*J 1 0.35 .556 <.0001  2.05 .152 <.0001  3.72 .057 .0239  1.62 0.206 .0119 
𝜃100*K 1 6.10 .014 <.0001  3.46 .063 <.0001  5.81 .018 .0374  3.34 0.070 .0245 
𝜃100*𝜎𝑢1
2  1 0.12 .725 <.0001  1.4 .237 <.0001  3.85 .053 .0247  0.03 0.874 .0002 
𝜃100*𝜎𝑣1
2  1 2.05 .152 <.0001  0.73 .393 <.0001  1.11 .295 .0071  1.76 0.188 .0129 
I*J 1 0.00 .968 <.0001  1.62 .203 <.0001  1.14 .287 .0074  0.69 0.408 .0051 
I*K 1 4.07 .044 <.0001  2.09 .148 <.0001  0.02 .875 .0002  1.49 0.226 .0109 
I*𝜎𝑢1
2  1 1.09 .296 <.0001  0.01 .933 <.0001  0.53 .468 .0034  0.80 0.374 .0059 
I*𝜎𝑣1
2  1 0.38 .539 <.0001  0.04 .840 <.0001  1.44 .233 .0093  0.73 0.394 .0054 
J*K 1 1.37 .241 <.0001  1.04 .309 .0005  3.81 .054 .0245  0.19 0.666 .0014 
J*𝜎𝑢1
2  1 0.16 .690 <.0001  72.68* <.0001 .0006  0.15 .695 .0010  0.22 0.641 .0016 
J*𝜎𝑣1
2  1 1.78 .182 <.0001  94.18* <.0001 <.0001  3.72 .057 .0239  1.08 0.302 .0079 
K*𝜎𝑢1
2  1 2.36 .124 <.0001  2.63 .105 .0158  1.96 .165 .0126  3.54 0.063 .0260 
K*𝜎𝑣1
2  1 3.81 .051 <.0001  2390.06* <.0001 .0011  1.98 .162 .0127  1.01 0.318 .0074 
𝜎𝑢1
2 *𝜎𝑣1
2  1 0.00 .990 <.0001  161.32* <.0001 <.0001  0.22 .644 .0014  1.45 0.231 .0107 
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Standard error and coverage proportion of the 95% confidence interval of the 
overall treatment effect estimate. The standard errors of the treatment effect estimates are 
used to construct confidence intervals around the estimated treatment effect, 𝛾100. The 
standard deviations of the effect estimates in a given condition can be used as an empirical 
approximation of the true standard error and therefore as a criterion to evaluate the standard 
error estimates. We looked at the relative standard error bias, which is the difference between 
the mean standard error estimate and the standard deviation of the estimate of the effect 
divided by the standard deviation of the estimate of 𝛾100 (Hoogland & Boomsma, 1998). The 
estimated standard error is independent of the analysis model [F(1, 44) = 0.81, p = .371, ŋ̂𝟐 = 
.0052]. We found that the number of studies [F(1, 44) = 11.9, p = < .001, ŋ̂𝟐= .0765] is the 
only design condition having a statistically significant medium influence on the relative 
standard error bias. Table 3 gives a complete overview of the effect of the other design 
conditions and interactions on the relative standard error bias. The values for the relative 
standard error biases are negative, which means that the standard error estimates are slightly 
smaller than expected. However, none of the conditions reports a relative standard error bias 
larger than 10% which is widely accepted as cut off score (Hoogland & Boomsma, 1998). 
From this, we conclude that the standard error of overall treatment effect is well estimated. In 
addition, the coverage proportion of the 95% confidence interval was calculated. The 
estimated coverage proportion ranges from .94 to .96 with an average across all condition of 
.95 which is what we expected. The coverage proportion of the 95% confidence intervals 
appears to be independent of the analysis model [F(1, 104) = 0.37, p = .544, ŋ̂𝟐 = .0027] and 
other design conditions (indicated by the rather low value for the ŋ̂𝟐 in Table 3). 
Bias and MSE of the between-study variance of the treatment effect estimate. In 
addition to the treatment effect estimate, we were interested in how accurate (i.e., relative 
bias) and precise (i.e., MSE) the between-study variance of the treatment effect is estimated. 
The analysis model (Analysis Model 1 vs Analysis Model 2) has no statistically significant 
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large effect on the relative bias [F(1, 128004) = 1.67, p = .196, ŋ̂𝟐 < .0001] and the MSE [F(1, 
128004) = 0.75, p = .386, ŋ̂𝟐 < .0001] of the estimated between-study variance. The between-
study variance [F(1, 128004) = 39.83, p < .001, ŋ̂𝟐 = .0003] and the between-case variance 
[F(1, 128004) = 26.41, p < .001, ŋ̂𝟐 = .0002] have a statistically significant but small effect on 
the relative bias. No other design conditions or interactions appear to have a statistically 
significant or large effect on the relative bias of the between-study variance estimate as 
indicated in Table 4. The relative bias exceeds the cut off criterion of 5% set by Boomsma and 
Hoogland (1998) in almost all conditions except when 30 studies are included and the 
between-case and between-study variance have equal values (i.e.,  𝜎𝑢2
2  = 𝜎𝑢2
2  = 2 or  𝜎𝑢2
2  = 𝜎𝑢2
2  
= 8). The relative bias ranges from 0.761% to 303.927%. The problematic large values are 
obtained in conditions characterized by an unequal amount of between-study and between-
case variance as illustrated in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Graphical display of the influence of the between-case variance and the between-
study variance on the relative bias of the between-study variance estimate in Simulation Study 
1 (i.e., no covariance is generated). σu1
2  indicates the between-case variance. The graphical 
display is for a subset for conditions as similar patterns where found for the other combination 
of conditions. Analysis Model 1 (i.e., no covariance is estimated) is used, the overall baseline 
𝜎𝑢1
2  
𝜎𝑢1
2  
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level is set to zero, the number of measurements, cases and studies is set to 20, 3, and 10 
respectively. 
Table 4 also displays the effects of the design conditions and interactions on the MSE of 
the between-study variance. From this table it is clear that no statistically significant large 
effects are identified. The values for the MSE range from 0.166 to 41.613. The largest MSE 
values correspond to the condition in which the largest relative bias was detected (i.e., unequal 
amount of between-case and between-study variance). 
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Table 4 
Results Simulation Study 1 (i.e., no Covariance is Generated) using Analysis Model 1 (no Covariance is Estimated). Evaluation of the Main Effects and Interaction Effects of 
Simulation Conditions on the Relative Bias and Mean Squared Error of the Between-Study Variance and Between-Case Variance Estimate 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. *p < .001. ŋ̂2 reflects the magnitude of the main effects and/or interaction effects on the relative bias and mean squared error.  ŋ̂2 can take on values between 0 and 1 ( 
small: ŋ̂2 ≤ .02, medium: ŋ̂2 = .03-.25, and large: ŋ̂2 ≥.26, Cohen, 1988). 𝜃100 = immediate treatment effect, I, J, and K = number of measurements, cases, and studies 
respectively. Interactions between two independent variables are indicated with a * in between the two independent variables (e.g., 𝜃100*I indicates an interaction between the 
immediate treatment effect and the number of measurements). 
 Between-Study Variance Estimate Between-Case Variance Estimate 
 Relative Bias Mean Squared Error Relative Bias Mean Squared Error 
Independent 
Variable 
df F p ŋ̂2  F p ŋ̂2  F p ŋ̂2  F p ŋ̂2 
𝜃100 1 0.48 .487 < .0001  0.02 .883 < .0001  1.89 .1690 < .0001  1.08 .2994 < .0001 
I 1 1.10 .294 < .0001  0.91 .340 < .0001  2.25 .1336 < .0001  1.15 .2832 < .0001 
J 1 1.27 .260 < .0001  0.97 .325 < .0001  0.32 .5688 < .0001  0.27 .6040 < .0001 
K 1 3.31 .069 < .0001  3.84 .050 < .0001  2.42 .1201 < .0001  1.57 .2104 < .0001 
𝜎𝑢1
2  1 26.41* <.0001 .0002  0.13 .721 < .0001  0.26 .6103 < .0001  2.22 .1360 < .0001 
𝜎𝑣2
2  1 39.83* <.0001 .0003  3.84 .050 < .0001  2.54 .1107 < .0001  1.57 .2105 < .0001 
𝜃100*I 2 2.12 .146 < .0001  1.33 .248 < .0001  3.88 .0488 < .0001  3.16 .0757 < .0001 
𝜃100*J 1 0.52 .471 < .0001  0.61 .434 < .0001  0.01 .9409 < .0001  1.49 .2219 < .0001 
𝜃100*K 1 0.44 .509 < .0001  0.02 .885 < .0001  0.72 .3963 < .0001  0.23 .6330 < .0001 
𝜃100*𝜎𝑢1
2  1 0.84 .360 < .0001  1.72 .190 < .0001  0.04 .8390 < .0001  0.51 .4738 < .0001 
𝜃100*𝜎𝑣1
2  1 0.46 .498 < .0001  0.02 .885 < .0001  0.71 .4002 < .0001  0.23 .6327 < .0001 
I*J 1 0.14 .709 < .0001  0.00 .980 < .0001  0.00 .9558 < .0001  1.58 .2087 < .0001 
I*K 1 1.06 .303 < .0001  0.90 .342 < .0001  0.95 .3289 < .0001  0.26 .6080 < .0001 
I*𝜎𝑢1
2  1 0.35 .556 < .0001  0.26 .613 < .0001  0.01 .9436 < .0001  0.56 .4525 < .0001 
I*𝜎𝑣1
2  1 1.07 .301 < .0001  0.90 .342 < .0001  0.96 .3281 < .0001  0.26 .6079 < .0001 
J*K 1 1.34 .247 < .0001  0.97 .324 < .0001  1.14 .2858 < .0001  0.00 .9670 < .0001 
J*𝜎𝑢1
2  1 0.92 .338 < .0001  0.36 .549 < .0001  1.03 .3103 < .0001  0.70 .4016 < .0001 
J*𝜎𝑣1
2  1 1.36 .243 < .0001  0.97 .324 < .0001  1.08 .2994 < .0001  < 0.00 .9672 < .0001 
K*𝜎𝑢1
2  1 3.28 .070 < .0001  3.84 .050 < .0001  4.42 .0356 < .0001  3.28 .0701 < .0001 
K*𝜎𝑣1
2  1 0.43 .512 < .0001  0.13 .722 < .0001  0.00 .9983 < .0001  0.87 .3517 < .0001 
𝜎𝑢1
2 *𝜎𝑣1
2  1 11.36 .001 .0001  0.13 .723 < .0001  0.00 .9752 < .0001  0.87 .3516 < .0001 
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Bias and MSE of the between-case variance of the treatment effect estimate. In 
addition to the estimated between-study variability in the treatment effect estimate, we were 
also interested in how accurate and precise the between-case variance of the treatment effect 
can be estimated using the three-level model. The relative bias [F(1, 128004) = 0.35, p = .554, 
ŋ̂𝟐 < .0001] and the MSE [F(1, 128004) = 0.44, p = .508, ŋ̂𝟐 < .0001] of the estimated 
between-case variance are independent of the analysis model. Also, no other design 
conditions have a significant influence on the relative bias and MSE as indicated in Table 4. 
The between-case variance estimate of the treatment effect does not exceeds the 5% criterion 
set by Boomsma and Hoogland (1998) except in the condition with a small amount of cases, a 
small amount of studies, a large amount of between study-variance and a small amount of 
between-case variance. Indeed the relative bias ranges from 0.0165% to 7.84%. This stands in 
contrast to the between-study variance estimates in which in almost all conditions biased 
estimates are obtained. In terms of the MSE, also smaller values are obtained compared to the 
between-study variance estimates. The range of the MSE is 0.0202 to 3.2793 (and is more 
than 13 times smaller than the MSE of the between-study variance). The conditions 
representing the largest values are all characterized by a small number of studies, a small 
number of cases and an unequal amount of between-case and between-study variance. 
Simulation Study 2 
In this second simulation study, we evaluated whether ignoring existing true covariance 
between the baseline level and the treatment effect has an effect on the overall treatment effect 
estimate (especially in terms of the standard error estimate and the coverage proportion of the 
95% confidence interval). We were also interested whether Analysis Model 2 (in which 
covariance was modelled) resulted in more accurate (i.e., relative bias) and precise (i.e., MSE) 
variance component estimates. 
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Bias and MSE of the overall treatment effect estimate. Similar to the first 
simulation study, the relative bias [F(1, 511538) = 0.03, p = .868, ŋ̂𝟐 < .0001] and the MSE 
[F(1, 511538) = 0.15, p = .709, ŋ̂𝟐 < .001] appear to be independent of the analysis model. 
Compared to the first simulation study, we have additional design factors, namely the 
covariance (between the baseline level and the treatment effect) at the second and the third 
level but also these designs conditions have no significant effect on the bias (see Table 5). 
Similar to the first simulation study, the absolute bias ranges from -1.022×10-4 to 0.070 and 
the conditions representing the largest bias are characterized by 10 studies and 3 cases. A 
complete overview of the absolute bias per analysis model and design condition can be 
obtained by the first author. 
Also in terms of the MSE, the same results were obtained as in Simulation Study 1: The 
MSE ranges from 0.066 to 1.166 and the largest MSE is found in the condition in which 10 
studies, 3 cases, and 40 measurement occasions are included in combination with a large amount 
of between-case variance (i.e., 𝜎𝑢1
2  = 8) and between-study variance (i.e., 𝜎𝑢1
2  = 8). The same 
influencing design conditions (and interactions) are found as in Simulation Study 1 (see Table 
5): The overall treatment effect can be estimated more precisely when the between-study and 
between-case variance are low. The MSE can further be reduced by including more units at 
level 2 and level 3 of the three-level model.  
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Table 5 
Results Simulation Study 2 (i.e., Covariance is Generated) using Analysis Model 1 (no Covariance is Estimated). Evaluation of the Main Effects and Interaction Effects of 
Simulation Conditions on the Bias, Mean Squared Error, Relative Standard Error Bias, and Coverage Proportion of the 95% Confidence Interval of the Treatment Effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. *p 
< .001. ŋ̂2 reflects the magnitude of the main effects and/or interaction effects on the relative bias, mean squared error, relative standard error bias and coverage proportion of the 
95% confidence interval. ŋ̂2 can take on values between 0 and 1 ( small: ŋ̂2 ≤ .02, medium: ŋ̂2 = .03-.25, and large: ŋ̂2 ≥.26, Cohen, 1988). 𝜃100 = immediate treatment effect, I, 
J, and K = number of measurements, cases, and studies respectively. Interactions between two independent variables are indicated with a * in between the two independent 
variables (e.g., 𝜃100*I indicates an interaction between the immediate treatment effect and the number of measurements). 
 Bias Mean Squared Error Relative Standard Error Bias Coverage Proportion 95% 
Confidence Interval 
Independent 
variable 
df F p ŋ̂2  F p ŋ̂2  F p ŋ̂2  F p ŋ̂2 
𝜃100 1 2.18 .139 <.0001  3.80 .051 <.0001  2.86 .0917 .0009  1.37 .2419 .0012 
I 1 0.40 .528 <.0001  3.77 .052 <.0001  1.52 .2181 .0003  0.15 .7028 .0001 
J 1 0.63 .426 <.0001  547.99* <.0001 .0009  51.77* <.0001 .0258  *38.60 <.0001 .0332 
K 1 0.29 .591 <.0001  40874.00* <.0001 .0675  169.22* <.0001 .0853  0.17 .6832 .0001 
𝜎𝑢1
2  1 2.37 .690 .0001  623.21* <.0001 .0031  46.11* <.0001 .0686  *25.02 <.0001 .0645 
𝜎𝑣2
2  1 0.98 .430 <.0001  13283.80* <.0001 .0658  287.23* <.0001 .4356  *145.61 <.0001 .3753 
𝜃100*I 2 4.54 .330 <.0001  1.00 .318 <.0001  2.05 .1531 .0005  4.85 .0281 .0042 
𝜃100*J 1 0.30 .586 <.0001  1.18 .277 <.0001  0.07 .7918 -.0005  0.60 .4408 .0005 
𝜃100*K 1 2.23 .135 <.0001  1.99 .158 <.0001  0.00 .9698 -.0005  0.42 .5188 .0004 
𝜃100*𝜎𝑢1
2  1 2.77 .400 <.0001  0.86 .460 <.0001  2.43 .0642 .0022  2.56 .0543 .0066 
𝜃100*𝜎𝑣1
2  1 0.04 .989 <.0001  5.09 .002 <.0001  0.79 .4979 -.0003  1.20 .3083 .0031 
I*J 1 1.68 .195 <.0001  6.94 .008 <.0001  1.81 .1796 .0004  2.11 .1475 .0018 
I*K 1 0.49 .486 <.0001  6.10 .014 <.0001  1.32 .2512 .0002  1.51 .2200 .0013 
I*𝜎𝑢1
2  1 0.39 .763 <.0001  0.97 .407 <.0001  2.64 .0491 .0025  2.51 .0582 .0065 
I*𝜎𝑣1
2  1 0.43 .729 <.0001  4.31 .005 <.0001  2.06 .1053 .0016  1.74 .1582 .0045 
J*K 1 0.90 .342 <.0001  105.51* <.0001 .0002  0.26 .6111 -.0004  0.29 .5879 .0003 
J*𝜎𝑢1
2  1 2.33 .730 <.0001  96.78* <.0001 .0005  1.31 .2697 .0005  0.53 .6606 .0014 
J*𝜎𝑣1
2  1 0.07 .976 <.0001  16.60* <.0001 .0001  13.44* <.0001 .0189  5.95 .0005 .0153 
K*𝜎𝑢1
2  1 1.36 .252 <.0001  3370.08* <.0001 .0167  3.51 .0154 .0038  1.86 .1351 .0048 
K*𝜎𝑣1
2  1 2.32 .730 <.0001  148.18* <.0001 .0007  1.31 .2713 .0005  0.47 .7016 .0012 
𝜎𝑢1
2 *𝜎𝑣1
2  1 1.35 .240 <.0001  25.09* <.0001 .0004  21.61* <.0001 .0941  *10.06 <.0001 .0778 
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Standard error and coverage proportion of the 95% confidence interval of the 
overall treatment effect estimate. Similar to Simulation Study 1, the relative standard error 
bias [F(1, 451) = 1.69, p = .194, ŋ̂𝟐 = .0009] and the coverage proportion of the 95% 
confidence interval [F(1, 451) = 1.91, p = .340, ŋ̂𝟐 = .0008] are independent of the analysis 
model. However, different design conditions are found to have a statistically significant and 
medium effect on the relative standard error bias (see Table 5) compared to Simulation Study 
1. There is a significant medium effect of the number of cases [F(1, 451) = 51.77, p <.0001, 
ŋ̂𝟐 = .0263], the number of studies [F(1, 451) = 169.22, p <.0001, ŋ̂𝟐 = .0859] and the 
covariance at the second level F(3, 451) = 46.11, p <.0001, ŋ̂𝟐 = .0702]. The covariance at the 
third level appears to have the largest impact [F(3, 451) = 46.11, p <.0001, ŋ̂𝟐 = .4373]. A 
statistically significant medium interaction effect is identified between the number of cases 
and the between-study covariance [F(3, 451) = 13.44, p <.0001, ŋ̂𝟐 = .0205] and between the 
covariance at the second level and the third level F(9, 451) = 21.61, p <.0001, ŋ̂𝟐 = .0987]. 
The large impact of the between-study covariance on the relative bias is illustrated in Figure 
5. The relative standard error bias is smaller than 5% if the between-study covariance is large. 
If the between-study covariance is small, than the relative standard error bias increases if the 
between-study variance becomes larger (i.e., 𝜎𝑢1
2  = 8). The results indicate that the relative 
bias standard error difference only exceeds the Hoogland and Boomsma’s criterion of 10% in 
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conditions characterized by a large between-case covariance and a small between-study 
covariance (this represents only 4.89% of the conditions). 
 
Figure 5. Graphical display of the influence of the between-study variance and the between-
study covariance on the relative bias of the treatment effect in Simulation Study 2 (Covariance 
Estimated). The graphical display is for a subset for conditions as similar patterns where 
found for the other combination of conditions. Analysis Model 1 (i.e., no covariance is 
estimated) is used, the overall baseline level is set to zero, the number of measurements, cases 
and studies is set to 20, 3, and 10 respectively, the between-case variance is set to 0 and the 
between-case covariance is set to a small value. 
In contrast to Simulation Study 1, we found statistically significant and medium to large 
effects of the design conditions on the coverage proportion of the 95% confidence interval (see 
Table 5). Indeed, the number of cases [F(1, 451) = 38.60, p < .001, ŋ̂𝟐 = .0332], the amount of 
between-case covariance [F(3, 451) = 25.02, p < .001, ŋ̂𝟐 = .0645] and the interaction between 
the amount of between-case covariance and the between-study covariance [F(9, 451) = 10.06, 
p < .0001, ŋ̂𝟐 = .0778] have a medium effect on the coverage proportion. In addition, the 
between-study covariance has a large effect [F(1, 451) = 145.61, p < .0001, ŋ̂𝟐 = .3753]. 
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However, no problematic values for the coverage proportion of the 95% confidence interval 
were found as, similar to Simulation Study 1, all values lay between .93 and .98.  
Bias and MSE of the between-study variance of the treatment effect estimate. 
There is no significant influence of the used analysis model on the relative bias [F(1, 511517) 
= 3.53, p = .060, ŋ̂𝟐 < .0001] and the MSE [F(1, 511517) = 1.93, p = .060, ŋ̂𝟐< .0001] of the 
between-study variance. Similar to Simulation Study 1, none of the design factors have a 
statistically significant large main effect on the relative bias. The same applies for the 
interaction effects. A complete overview of the main effects and the interaction effects 
accordingly with their effect sizes (i.e., ŋ̂𝟐) are displayed in Table 6. From this table we can 
deduce that the ŋ̂𝟐’s are smaller than .0001 for all main effects and interaction effects which 
indicates no major influences on the relative bias. The same applies for the MSE of the 
estimated between-study variance of the treatment effect as indicated in Table 6.  
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Table 6 
Results Simulation Study 2 (i.e., Covariance is Generated) using Analysis Model 1 (no Covariance is Estimated). Evaluation of the Main Effects and Interaction Effects of 
Simulation Conditions on the Relative Bias and Mean Squared Error of the Between-Study Variance and Between-Case Variance Estimate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. All values for  ŋ̂2 are smaller than .0001 indicating a small effect (ŋ̂2 ≤ .02). Main Effects and Interaction Effects of Simulation Conditions on the Relative Bias and Mean 
Squared Error of the Between-Study  Variance Estimate and the Between-Case Variance Estimate 
 Between-Study Variance  Between-Case Variance 
 Relative Bias Mean Squared Error  Relative bias  Mean Squared Error 
Independent 
variable 
Df F p ŋ̂𝟐  F p ŋ̂𝟐   F p ŋ̂𝟐  F p ŋ̂𝟐 
𝜃100 1 0.64 0.424 <.0001  0.74 0.389 <.0001   1.70 0.1923 <.0001  1.58 0.2090 <.0001  
I 1 0.71 0.400 <.0001  0.85 0.357 <.0001   0.56 0.4537 <.0001  0.64 0.4250 <.0001  
J 1 0.35 0.552 <.0001  0.8 0.372 <.0001   0.36 0.5479 <.0001  0.60 0.4372 <.0001  
K 1 2.29 0.130 <.0001  1.36 0.243 <.0001   1.49 0.2229 <.0001  1.34 0.2472 <.0001  
𝜎𝑢0𝑢1  3 2.64 0.048 <.0001  1.32 0.266 <.0001   2.71 0.0432 <.0001  1.80 0.1454 <.0001  
𝜎𝑣0𝑣1  3 1.78 0.149 <.0001  1.47 0.219 <.0001   1.62 0.1832 <.0001  1.01 0.3881 <.0001  
𝜃100*I 1 1.39 0.238 <.0001  1.49 0.223 <.0001   0.89 0.3464 <.0001  0.90 0.3441 <.0001  
𝜃100*J 1 1.03 0.311 <.0001  1.42 0.233 <.0001   0.63 0.4266 <.0001  0.86 0.3546 <.0001  
𝜃100*K 1 0.04 0.849 <.0001  0.37 0.541 <.0001   0.42 0.5161 <.0001  0.92 0.3370 <.0001  
𝜃100*𝜎𝑢0𝑢1 3 1.87 0.133 <.0001  1.35 0.255 <.0001   2.64 0.0480 <.0001  1.89 0.1293 <.0001  
𝜃100*𝜎𝑣0𝑣1 3 0.19 0.906 <.0001  0.44 0.722 <.0001   0.56 0.6440 <.0001  0.68 0.5650 <.0001  
I*J 1 3.45 0.063 <.0001  1.93 0.165 <.0001   3.21 0.0733 <.0001  2.05 0.1518 <.0001  
I*K 1 0.06 0.804 <.0001  0.45 0.503 <.0001   0.00 0.9785 <.0001  0.25 0.6165 <.0001  
I*𝜎𝑢0𝑢1 3 2.16 0.090 <.0001  1.49 0.215 <.0001   1.01 0.3875 <.0001  0.84 0.4726 <.0001  
I*𝜎𝑣0𝑣1 3 0.49 0.693 <.0001  0.65 0.584 <.0001   0.60 0.6179 <.0001  0.86 0.4613 <.0001  
J*K 1 0 0.959 <.0001  0.41 0.520 <.0001   0.01 0.9342 <.0001  0.23 0.6307 <.0001  
J*𝜎𝑢0𝑢1  3 1.34 0.259 <.0001  1.43 0.232 <.0001   0.72 0.5380 <.0001  0.80 0.4925 <.0001  
J*𝜎𝑣0𝑣1  3 0.38 0.768 <.0001  0.61 0.611 <.0001   0.33 0.8019 <.0001  0.82 0.4812 <.0001  
K*𝜎𝑢0𝑢1  3 1.05 0.370 <.0001  0.82 0.484 <.0001   1.52 0.2059 <.0001  1.07 0.3602 <.0001  
K*𝜎𝑣0𝑣1 3 2.34 0.071 <.0001  1.66 0.173 <.0001   0.97 0.4077 <.0001  1.09 0.3517 <.0001  
𝜎𝑢0𝑢1*𝜎𝑣0𝑣1 9 0.88 0.544 <.0001  0.91 0.516 <.0001   1.00 0.4412 <.0001  0.81 0.6054 <.0001  
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We sorted the relative bias from small to large per analysis model. For Analysis Model 
1, we found the relative bias ranging from 0.01% to 26.9%, whereas the relative bias ranges 
from 0.04×10-4 % to 23.5% for Analysis Model 2. The smallest values for the relative bias were 
found when the number of studies is 30 (independent of other design conditions). Indeed, values 
for the relative bias lower than the cut off criterion of 5% (i.e., Hoogland & Boomsma, 1998) 
all have 30 studies in common, which represents 43% out of the 256 design conditions for 
Analysis Model 1 and 43% out of the 256 conditions for Analysis Model 2. A similar amount 
of biased variance estimates are obtained for both models. From these results we conclude that 
there is no clear evidence that Analysis Model 2 results in more accurate between-study 
variance estimates (which confirms the ANOVA’s conducted as primarily analysis).  
Also in terms of the precision of the estimated between-study variance (i.e., MSE), there 
is no clear advantage of using Analysis Model 2 where covariance is modelled [F(1, 511506) = 
1.93, p = .165, ŋ̂𝟐 < .0001]. Table 6 also illustrates that there are no statistically significant and 
large main effects or interaction effects on the MSE of the between-study variance of the overall 
treatment effect. The range for the MSE is similar across the two analysis models, namely 
between 0.145 and 13.306 for Analysis Model 1 and between 0.144 and 13.445 for Analysis 
Model 2. When sorting the MSE from small to large, we found that the conditions representing 
the smallest MSE all have 30 studies and a small amount of between-study variability in 
common. The largest MSE occurs when 10 studies with a large between-case variance is 
presented. A complete overview of the relative bias and the MSE per design condition and per 
analysis model can be requested by the first author. 
Bias and MSE of the between-case variance of the treatment effect estimate. 
Similar to the estimated between-study variance, the relative bias of the between-case 
variance is not significantly influenced by the used analysis model; F(1, 511506) = 4.20, p = 
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.040, ŋ̂𝟐 < .0001). No design conditions or interactions between conditions have a significant 
or large influence on the relative bias of the between-case variance of the treatment effect as 
indicated in Table 6. For Analysis Model 1, the relative bias of the between-case variance of 
the treatment effect ranges from -0.386% to 14.7% and for Analysis model 2 from -5.750×10-
4% to -7.7. This means that the range of the relative bias using Analysis Model 1 is almost 
twice as large compared to Analysis Model 2. We found that in 92.97% of the conditions the 
relative bias is lower than the 5% cut off criterion if Analysis Model 2 is used whereas this is 
only 61.33% if Analysis Model 1 is used. Although no statistically significant and large effect 
of the analysis model on the relative bias is found (see Table 6), the relative bias is smaller in 
all conditions using Analysis Model 2. The largest difference in relative bias occurs in 
conditions having a small number of level 1, level 2 and level 3 units with a small amount of 
between-case and between-study variance. The largest difference equals 10%.  
 In terms of the MSE of the estimated between-case variance of the treatment effect, no 
statistically significant and large effect of the analysis model; F(1, 511506) = 2.05, p = .209 ŋ̂𝟐 
< .0001) was found. The same accounts for the design conditions and interactions (see Table 
6). The largest differences in MSE are observed in the conditions representing a large amount 
of between-study and between-case variance, accordingly with large values for the covariance. 
The MSE using Analysis Model 2 is smaller than or equal to the MSE using Analysis Model 1 
in 76% of the conditions.  
Bias and MSE of between-case covariance and between-study covariance 
estimates. In the second simulation study where covariance is modelled and estimated (i.e., 
Analysis Model 2), the preliminary ANOVA indicates that none of the design conditions have 
a statistically significant or large influence on the relative bias and MSE of the estimated 
between-study covariance as indicated in Table 7. The estimated between-study covariance is 
extremely biased in all conditions and ranges from 169% to 206% (see Table 10 for a 
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complete overview of the relative bias per design condition). None of the design conditions 
succeeds in reducing the bias. Also the MSE appears to be rather high having values ranging 
from 1.13 to 124.22. This indicates that the three-level model is unable to estimate the 
between-study covariance accurately and precisely when there is in reality non-zero between-
study covariance. Especially in the condition representing a large amount of between-study 
covariance extremely biased and imprecise estimates are obtained. 
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Table 7 
 Results Simulation Study 2 (i.e., Covariance is Generated) using Analysis Model 1 (no Covariance is Estimated). Evaluation of the Main Effects and Interaction Effects of 
Simulation Conditions on the Relative Bias and Mean Squared Error of the Between-Study Covariance and the Between-Case Covariance Estimate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. ŋ̂2 reflects the magnitude of the main effects and/or interaction effects on the relative bias and mean squared error. ŋ̂2 can take on values between 0 and 1 ( small: ŋ̂2 ≤ .02, 
medium: ŋ̂2 = .03-.25, and large: ŋ̂2 ≥.26, Cohen, 1988). 𝜃100 = immediate treatment effect, I, J, and K = number of measurements, cases, and studies respectively. 𝜎𝑢0𝑢1 , 𝜎𝑣0𝑣1  
indicate the between-case covariance and between-study covariance respectively. 𝜎𝑢1
2  and 𝜎𝑣1
2  indicate the between-case
 Between-Study Covariance Between-Case Covariance 
 Relative Bias Mean Squared Error Relative Bias Mean Squared Error 
Independent 
Variable 
df F p ŋ̂𝟐  F p ŋ̂𝟐  F p ŋ̂𝟐  F p ŋ̂𝟐 
𝜃100 1 1.52 0.2181 <.0001  2.03 0.154 <.0001  1.40 0.236 <.0001  0.90 0.3414 <.0001 
I 1 1.17 0.2791 <.0001  1.86 0.173 <.0001  0.69 0.405 <.0001  0.51 0.4759 <.0001 
J 1 1.45 0.2289 <.0001  1.85 0.173 <.0001  0.72 0.397 <.0001  0.51 0.4762 <.0001 
K 1 0.92 0.3374 <.0001  0.06 0.808 <.0001  1.25 0.264 <.0001  1.45 0.2292 <.0001 
𝜎𝑢0𝑢1  3 1.87 0.1320 <.0001  2.08 0.101 <.0001  2.70 0.044 <.0001  1.59 0.1900 <.0001 
𝜎𝑣0𝑣1  3 0.83 0.4744 <.0001  0.73 0.532 <.0001  1.38 0.245 <.0001  1.40 0.2413 <.0001 
𝜃100*I 1 1.22 0.2684 <.0001  1.86 0.172 <.0001  0.77 0.380 <.0001  1.50 0.2213 <.0001 
𝜃100*J 1 1.28 0.2583 <.0001  1.87 0.172 <.0001  0.81 0.369 <.0001  1.50 0.2213 <.0001 
𝜃100*K 1 0.31 0.5766 <.0001  0.05 0.831 <.0001  0.15 0.699 <.0001  0.28 0.5960 <.0001 
𝜃100*𝜎𝑢0𝑢1 3 1.78 0.1480 <.0001  2.06 0.104 <.0001  2.09 0.099 <.0001  1.89 0.1293 <.0001 
𝜃100*𝜎𝑣0𝑣1 3 0.49 0.6874 <.0001  0.69 0.559 <.0001  0.51 0.678 <.0001  0.33 0.8026 <.0001 
I*J 1 2.63 0.1046 <.0001  2.11 0.146 <.0001  3.69 0.055 <.0001  2.64 0.1044 <.0001 
I*K 1 0.13 0.7196 <.0001  0.02 0.880 <.0001  0.00 0.960 <.0001  0.08 0.7707 <.0001 
I*𝜎𝑢0𝑢1 3 1.66 0.1737 <.0001  1.88 0.130 <.0001  1.27 0.282 <.0001  1.30 0.2719 <.0001 
I*𝜎𝑣0𝑣1 3 0.77 0.5103 <.0001  0.65 0.581 <.0001  0.59 0.623 <.0001  0.42 0.7391 <.0001 
J*K 1 0.21 0.6461 <.0001  0.02 0.880 <.0001  0.00 0.951 <.0001  0.09 0.7704 <.0001 
J*𝜎𝑢0𝑢1  3 1.77 0.1510 <.0001  1.88 0.130 <.0001  1.25 0.289 <.0001  1.30 0.2717 <.0001 
J*𝜎𝑣0𝑣1  3 0.85 0.4638 <.0001  0.65 0.581 <.0001  0.58 0.627 <.0001  0.42 0.7391 <.0001 
K*𝜎𝑢0𝑢1  3 1.41 0.2388 <.0001  1.28 0.278 <.0001  1.44 0.229 <.0001  1.61 0.1843 <.0001 
K*𝜎𝑣0𝑣1 3 0.49 0.6899 <.0001  0.05 0.984 <.0001  0.76 0.516 <.0001  0.73 0.5337 <.0001 
𝜎𝑢0𝑢1*𝜎𝑣0𝑣1 9 0.80 0.6165 <.0001  0.71 0.701 <.0001  0.97 0.460 <.0001  0.74 0.6716 <.0001 
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 For the estimated between-case covariance no statistically significant or large effects of 
the design conditions on the relative bias and the MSE were found as indicated in Table 7. The 
relative bias of the between-case covariance ranges from 0.01% to 14.74%. The between-case 
covariance estimates are unbiased (i.e., smaller than 5%) if there are at least 30 studies included 
(independent of other conditions). In case only 10 studies are available for synthesis, then the 
between-case covariance estimate is unbiased if each study includes at least 7 cases. In these 
conditions, the between-case covariance is most precisely estimated (indicated by smaller 
values for the MSE). The MSE ranges from 0.011 to 2.18 and the largest values coincidence 
with the conditions having the largest relative bias (i.e., 10 studies and 3 cases). This indicates 
that the three-level model is appropriate to estimate the between-case covariance accurately and 
precisely when there is in reality non-zero between-case covariance at least when there are 7 
cases within each study included. When only 3 cases are included, than combining at least 30 
studies is necessary. 
In sum, an interesting finding is that the between-study covariance is not well estimated 
in terms of accuracy and precision using the three-level model and therefore can induce biased 
between-study variance estimates. In contrast, the between-case covariance estimates tend to 
be unbiased and well estimated. This explains why the between-case variances are unbiased in 
most conditions and more precisely estimated compared to the between-study variance 
estimates. These results indicate why Analysis Model 2 does not outperform Analysis Model 1 
when covariance is generated. 
Empirical Illustration 
We use the meta-analysis of single-case studies conducted by Denis et al. (2011). They 
collected studies where the effectiveness of a treatment for self-injurious behavior in people 
with profound intellectual disabilities was investigated. In particular, 18 studies were collected 
where non-aversive, non-intrusive forms of reinforcement were examined. The single-case 
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experiments were coded as AB phase designs. We analyzed the data by modeling possible 
covariance between the regression coefficients (i.e., Analysis Model 2) and ignoring possible 
covariance between the regression coefficients (i.e., Analysis Model 1). 
The results indicate that, as expected, the ignorance of existent covariance has no large 
effect on the estimated treatment effects. The overall treatment effect estimates are statistically 
significant at the .01 level and equal -2.43 [t(18.2) = –.67, p < .01] for Analysis Model 1 and -
2.41 [t(18.2) = -4.71, p < .01] for Analysis Model 2. From these analyses we can conclude that 
the treatment is effective to reduce self-injurious behavior. 
The estimated between-study variance of the treatment effect is slightly larger when 
Analysis Model 1 is used (?̂?𝑣1
2 = 4.34, Z = 2.59, p = < .01) in comparison to Analysis Model 2 
(?̂?𝑣1
2 = 3.96 , Z = 2.59, p = < .01). We also identified a difference between the estimated between-
case variance of the treatment effect, which equals 0.54 [Z = 1.49, p = .07], for Analysis Model 
1 and 1.02 [Z = 1.71, p = .04] for Analysis Model 2. The estimated covariance, in Analysis 
Model 2 between the baseline level and the treatment effect equals, -0.92 [Z = -1.80, p = .07] 
and -3.09 [Z = –1.62, p = .10] at level 2 and level 3 respectively. This means that a large 
estimated baseline level at level 2 and level 3 go together with a small estimated treatment 
effect. 
This empirical example indicates that the fixed effect estimates are independent of the 
analysis model (i.e., the treatment is found to be effective to reduce self-injurious behavior). 
For the variance components estimates, we can feel confident in the estimate of the between-
case variance and covariance. However, caution is needed when interpreting the between-study 
variance and covariance as biased and less precise estimates can be obtained, especially when 
less than 30 studies are included (as is the case in this empirical example). In sum, if the research 
interest lies in the between-case variance estimates and the treatment effect estimate, the 
multilevel model (either Analysis Model 1 or Analysis Model 2) can be applied to the dataset 
of Denis et al. (2011). If the research interest also lies in the between-case covariance estimate 
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only Analysis Model 2 can be used. In this empirical example, the multilevel model is not 
appropriate to obtain accurate and reliable between study (co)variances as less than 30 studies 
are included. If the research interest lies in the between-study variance we advised to search in 
the literature for similar focused single-case studies to include in the synthesis. 
Discussion 
General Conclusion 
The main purpose of this study was to evaluate the consequences of misspecifying the 
between-case and between-study covariance matrix on the estimation of the treatment effects, 
and their corresponding mean squared error, standard errors, coverage proportion of the 95% 
confidence interval and variance and covariance components. Because it is not always obvious 
how to define the covariance matrix, it is important to examine the degree to which the treatment 
effect estimates and the variance estimates are sensitive to changes in the specification of the 
covariance matrix. 
In contexts of SCD data, only the effects of level-1 residuals’ covariance 
misspecification have been studied before for a two-level model (Ferron, et al. , 2009). Previous 
methodological work devoted to misspecification of the (co)variance matrix has been conducted 
in contexts other than multilevel modeling of SCDs (Berkhof & Kampen, 2004; Kwok et al., 
2007; Jahng, 2008; Moerbeek, 2004; Singer & Willett; Van den Noortgate & Onghena, 2005). 
Level-2 and level-3 covariance misspecification issues in the SCD three-level modeling 
framework have not yet been investigated. Indeed, previous research concerning the three-level 
model for SCD data focused on the estimate of the overall treatment effect, and of the between-
case and between-study variance of the overall treatment effect. The between-case and between-
study residuals were each assumed to be independently, identically, and normally distributed 
with mean zero and homogeneous variance, and thus a diagonal covariance structure was 
assumed. To date, no research has focused on the consequences of ignoring truly non-zero 
covariances in the context of multilevel modeling of SCD data. However, this is urgent as it 
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provides a more complete understanding of misspecification issues in contexts of three-level 
modeling of SCD data. 
In Simulation Study 1, we compared the scenario in which covariance is not simulated 
and not estimated (i.e., Analysis Model 1) with the scenario in which covariance is not 
simulated, but is estimated (i.e., Analysis Model 2). No statistically significant and large 
differences between Analysis Model 1 and Analysis Model 2 were found in terms of both the 
overall treatment effect estimate and variance components estimates. The overall treatment 
effect estimate as well as the between-case variance is estimated accurately and precisely. 
However, the between-study variance estimates are biased and not precisely estimated when 
the between-case variance and between-study variance have different values and when less than 
30 studies are included. This confirms previous research devoted to multilevel modeling of 
single cases (Moeyaert et al. 2013a, 2013b; Owens & Ferron, 2012). In sum, if there is in reality 
no covariance, using Analysis Model 1 or Analysis Model 2 does not make a difference both in 
terms of the overall treatment effect or variance estimates. Caution is needed when estimating 
the between-study variance because in certain conditions biased and less precise estimates are 
obtained. 
 In the second simulation study, we compared the condition where covariance is 
simulated, but ignored in the analysis (i.e., Analysis Model 1) with the scenario where 
covariance is simulated and estimated in the analysis (i.e., Analysis Model 2). The overall 
treatment effect is equally well estimated using both analysis models. Surprisingly, Analysis 
Model 2 did not outperform Analysis Model 1 for the variance component estimates. Also in 
this simulation study, biased and less precise between-study (co)variance estimates are obtained 
in contrast to the between-case (co)variance estimates both when Analysis Model 1 and 
Analysis Model 2 are applied. We expected biased variance estimates for Analysis Model 1, 
because the model is misspecified by ignoring true existing covariance. However, also the 
correctly specified model (i.e., Analysis Model 2) resulted in biased and not well estimated 
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between-study variance estimates. This can be cause by the extremely biased between-study 
covariance estimates.  
As a consequence, we advise researchers interested in estimating the overall treatment 
effect across cases and across studies (in similar contexts as the conditions included in this 
simulation study) to use either the analysis model including or not including covariance. 
However, when the research interest lies in the (co)variance components estimates, either 
Analysis Model 1 or Analysis Model 2 result in unbiased between-case (co) variance estimates. 
Caution is warranted when the between-study (co) variances are of interest. 
 Further research is needed in this context, because we expected that the model in which 
covariance was modelled would outperform the model in which covariance was ignored, but 
this was not the case. Also the between-study covariance estimates were biased and not well 
estimated. Therefore, there is a need to search for alternative estimation procedures such as 
bootstrapping and Bayesian estimation recommended in contexts dealing with small sample 
sizes as is the case in single-case research. 
Limitations 
As with any simulation study, one of the major potential limitations of this study is the 
generalizability of the findings. Further research is needed for the applicability of current 
findings to a broader range of conditions. We partly addressed this limitation by including 
realistic conditions based on several re-analyses of meta-analyses. The conditions are quite 
representative for the research field of single-case experiments in educational settings. 
In current research, we only investigated the basic MBD including one predictor at the 
first level (i.e., dummy coded variable indicating the treatment effect). We excluded models 
with multiple predictors at level 2 and level 3, models using unbalanced data, non-linear models, 
reversal and alternating designs, and other complex models.  
In this study, we only included covariance at the second and third level, which means 
that we ignored possible autocorrelation at the first level. The issue of autocorrelation itself 
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deserves separate research and is beyond the scope of this paper (Baek & Ferron, 2013). In 
Simulation Study 2, we generated covariance simultaneously at level 2 and level 3 (taking on 
different values and crossing these values) and analyzed the generated datasets including or not 
including covariance at level 2 and level 3. We did not include an analysis model in which 
covariance was only modelled at one level and ignored at the other level, which would be 
interesting for further research. 
The combination of SCD data over studies may be difficult if studies are too different. 
Studies may for instance differ in measuring the treatment effect. We can handle this by the 
inclusion of covariates indicating certain study and even case characteristics to model this 
heterogeneity. Another possibility is standardizing the data or using a multivariate three-level 
model. 
Other approaches to estimate the treatment effects and variances in these treatment 
effects when the variance structures are misspecified should be considered in future research, 
such as the sandwich estimator (i.e., cluster-robust or Huber estimators). Even when the 
covariance matrices are misspecified, the sandwich estimator is asymptotically consistent 
(Raudenbush & Bryck, 2002; Hedges, Tipton, & Johnson, 2010). It would be a useful 
contribution to compare the standard errors and coverage proportion of the 95% confidence 
intervals constructed with the sandwich estimator to those constructed using the model-based 
estimators in the misspecified model. 
Furthermore, the misspecification of the covariance matrix is only one aspect to test the 
robustness of the three-level modeling approach. Further research is needed to evaluate other 
issues such as non-normal data and not identical distributed errors. However, as no previous 
research yet focused on misspecification of the covariance matrix in contexts of multilevel 
modeling of single-cases, this study provides some important insights. We advise single-case 
researchers to consider use of the three-level model, either modeling or ignoring covariance, 
when the research interest lies in the fixed effects or the between-case variance. If the research 
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interest lies in the between-case covariance the three-level model taking into account covariance 
can be used. The three-level models appear to be less appropriate to estimate between-study 
(co)variance, especially when there are less than 30 studies included. 
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